Researchers from Nanjing University and affiliated organizations have published the outcomes of a study that aimed to investigate the role of cadherin 4 (CDH4) in the metastatic cascade of papillary thyroid cancer (PTC).
Children’s Hospital Los Angeles (CHLA) has received a multiyear $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors. The CIRM funding will support further CHLA research into harnessing chimeric antigen receptor (CAR) T-cell therapy.
Scientists from First Affiliated Hospital Bengbu Medical College and affiliated organizations have studied the role of the RNA-binding ubiquitin ligase MEX3C in lung adenocarcinoma (LUAD).
C4 Therapeutics Inc. has entered into a license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins.
Global interest in radiopharmaceuticals is soaring, and the global radiopharma market is expected to grow 10% over the next decade to $13.67 billion by 2032, according to a new report by Precedence Research.
China’s NMPA has approved Carsgen Therapeutics Holdings Ltd.’s NDA for its B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy, zevorcabtagene autoleucel (CT-053, zevor-cel), for treating adults with relapsed or refractory (r/r) multiple myeloma (MM) who have progressed after at least three prior lines of therapy, including a proteasome inhibitor and immunomodulatory agent.
As Cardiff Oncology Inc. dosed the first patient in its phase II study of onvansertib (CRDF-004) in a first-line setting to treat RAS-mutated metastatic colorectal cancer (mCRC), the company also revealed positive efficacy data from its discontinued phase II of onvansertib as a second-line treatment of bevacizumab-naïve RAS-mutated mCRC.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Sravathi AI Technology Pvt Ltd. has disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
RSS
